Caribou Biosciences Inc (CRBU) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Caribou Biosciences Inc   (NASDAQ: CRBU)

Caribou Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Caribou Biosciences Inc in the second quarter 2026?
Caribou Biosciences Inc recorded a cumulative net loss of $-103 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -89.11%.

Within the Biotechnology & Pharmaceuticals industry 73 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2043 to 3545.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -40.95 % -53.04 % -51.7 % -49.56 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -103 -133 -148 -157 -164
Return On Equity (TTM) -89.11 % -100.13 % -91.52 % -80.77 % -71.61 %
CRBU's Total Ranking # 3545 # 2043 # 2799 # 3137 # 2885
Equity (TTM) in Millions 98 102 122 142 166
Seq. Equity Change -3.84 % -16.5 % -13.87 % -14.62 % -23.52 %
Seq. Net Income Change - - - - -

Back to CRBU Management Effectiveness >> CRBU's 5 Years Annual ROE >> Compare CRBU ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 74
Sector # 533
Overall # 3545

Return On Equity Statistics
High Average Low
-22.55 %
-48.81 %
-100.13 %
(Jun 30 2022)   (Mar 31 2026)



  News about Caribou Biosciences Inc Return on Equity ROE

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Caribou Biosciences Faces Legal and Financial Storm While Advancing Groundbreaking TrialsIn a landscape characterized by rapid advancements in biotechnology, Caribou Biosciences, Inc. (NASDAQ: CRBU) finds itself at a critical crossroads, navigating through a maelstrom of legal challenges and mounting financial difficulties even as it embarks on game-changing clinical trials. The company s recent initiation of the CB-010 GALLOP Phase 1 study in lupus, and progress in its CB-012 AMpLify Phase 1 trial for relapsed/refractory acute myeloid leukemia (r/r AML), underscores its commitment to unlocking the potential of genome editing. However, this commitment is shadowed by a deteriorating financial outlook and a serous class action lawsuit that threaten to undermine investor confidence. Trial Progress Amid Financial ConcernsCaribou’s recent press release highlights its advancement in two pivotal areas of drug development. The initiation of the CB-010 GALLOP Phase 1 trial in lupus marks a significant step for a company striving to redefine treatment paradigms in serious autoimmune conditions. Concurrently, the CB-012 AMpLify trial has reached dose level 4, reporting no dose-limiting toxicities (DLTs) in patients at level 3, paving the way for enrolling more individuals in this promising vein of research.



CRBU Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 122 253 368 301 388
Y / Y Equity Change -51.7 % -31.34 % 22.44 % -22.42 % -
Net Income in Millions -148 -149 -102 -99 -67
Y / Y Net Income Change - - - - -
Return On Equity -121.24 % -58.95 % -27.71 % -33.04 % -17.26 %

Back to CRBU Management Effectiveness >> CRBU's 5 Years Annual ROE >> Compare CRBU ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CRBU's' Return on Equity at Yahoo Finance
CRBU's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CRBU's Competitors
Subscribers only: Roe for Caribou Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for CRBU's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-02T20:50:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.